$VXRT Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Vaxart, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Vaxart, Inc.. Get notifications about new insider transactions in Vaxart, Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 07 2008 | NABI | Aviragen Therapeut ... | Kessler Paul D. | SVP Clinical, Med. ... | Sell | S | 3.78 | 30 | 113 | 44,330 | 44.4 K to 44.3 K (-0.07 %) |
| Mar 07 2008 | NABI | Aviragen Therapeut ... | FAHIM RAAFAT E F | President and CEO | Sell | S | 3.78 | 400 | 1,512 | 122,167 | 122.6 K to 122.2 K (-0.33 %) |
| Mar 07 2008 | NABI | Aviragen Therapeut ... | FAHIM RAAFAT E F | President and CEO | Sell | S | 3.77 | 200 | 754 | 122,567 | 122.8 K to 122.6 K (-0.16 %) |
| Mar 07 2008 | NABI | Aviragen Therapeut ... | FAHIM RAAFAT E F | President and CEO | Sell | S | 3.77 | 250 | 943 | 122,767 | 123 K to 122.8 K (-0.20 %) |
| Mar 07 2008 | NABI | Aviragen Therapeut ... | FAHIM RAAFAT E F | President and CEO | Sell | S | 3.76 | 2,725 | 10,246 | 123,017 | 125.7 K to 123 K (-2.17 %) |
| Mar 07 2008 | NABI | Aviragen Therapeut ... | FAHIM RAAFAT E F | President and CEO | Sell | S | 3.75 | 1,825 | 6,844 | 125,742 | 127.6 K to 125.7 K (-1.43 %) |
| Mar 07 2008 | NABI | Aviragen Therapeut ... | FAHIM RAAFAT E F | President and CEO | Sell | S | 3.75 | 2,100 | 7,877 | 127,567 | 129.7 K to 127.6 K (-1.62 %) |
| Mar 06 2008 | NABI | Aviragen Therapeut ... | Siegel Jordan I | Sr. VP Fin. & Admin ... | Sell | S | 3.80 | 1,900 | 7,220 | 85,657 | 87.6 K to 85.7 K (-2.17 %) |
| Mar 06 2008 | NABI | Aviragen Therapeut ... | Siegel Jordan I | Sr. VP Fin. & Admin ... | Sell | S | 3.78 | 300 | 1,134 | 87,557 | 87.9 K to 87.6 K (-0.34 %) |
| Mar 06 2008 | NABI | Aviragen Therapeut ... | Siegel Jordan I | Sr. VP Fin. & Admin ... | Sell | S | 3.80 | 3,200 | 12,160 | 87,857 | 91.1 K to 87.9 K (-3.51 %) |
| Mar 06 2008 | NABI | Aviragen Therapeut ... | Siegel Jordan I | Sr. VP Fin. & Admin ... | Sell | S | 3.80 | 2,100 | 7,982 | 91,057 | 93.2 K to 91.1 K (-2.25 %) |
| Jan 24 2008 | NABI | Aviragen Therapeut ... | FAHIM RAAFAT E F | President and CEO | Grant | A | 0.00 | 7,000 | 0 | 183,730 | 176.7 K to 183.7 K (+3.96 %) |
| Jan 24 2008 | NABI | Aviragen Therapeut ... | FAHIM RAAFAT E F | President and CEO | Grant | A | 0.00 | 50,000 | 0 | 176,730 | 126.7 K to 176.7 K (+39.45 %) |
| Oct 17 2007 | NABI | Aviragen Therapeut ... | Hudson Leslie | Interim President & ... | Grant | A | 0.00 | 48,000 | 0 | 79,759 | 31.8 K to 79.8 K (+151.14 %) |
| Oct 17 2007 | NABI | Aviragen Therapeut ... | Hudson Leslie | Interim President & ... | Grant | A | 0.00 | 20,000 | 0 | 31,759 | 11.8 K to 31.8 K (+170.08 %) |
| Aug 17 2007 | NABI | Aviragen Therapeut ... | Hudson Leslie | Interim President & ... | Sell | D | 0.00 | 1,307 | 0 | 11,759 | 13.1 K to 11.8 K (-10.00 %) |
| May 22 2007 | NABI | Aviragen Therapeut ... | SUDOVAR STEPHEN | Director | Option Exercise | A | 5.20 | 20,000 | 104,000 | 20,000 | |
| May 22 2007 | NABI | Aviragen Therapeut ... | Siegel Jordan I | Sr. VP, Fin., CFO a ... | Option Exercise | A | 5.20 | 90,000 | 468,000 | 90,000 | |
| May 22 2007 | NABI | Aviragen Therapeut ... | Siegel Jordan I | Sr. VP, Fin., CFO a ... | Grant | A | 0.00 | 30,000 | 0 | 90,000 | 60 K to 90 K (+50.00 %) |
| May 22 2007 | NABI | Aviragen Therapeut ... | COX GEOFFREY F | Non-executive Chair ... | Option Exercise | A | 5.20 | 40,000 | 208,000 | 40,000 | |
| May 22 2007 | NABI | Aviragen Therapeut ... | LYNCH TIMOTHY P | Director | Option Exercise | A | 5.20 | 20,000 | 104,000 | 20,000 | |
| May 22 2007 | NABI | Aviragen Therapeut ... | LYNCH TIMOTHY P | Director | Grant | A | 5.20 | 3,846 | 19,999 | 3,846 | 0 to 3.8 K |
| May 22 2007 | NABI | Aviragen Therapeut ... | JENCKES LINDA | Director | Option Exercise | A | 5.20 | 20,000 | 104,000 | 20,000 | |
| May 22 2007 | NABI | Aviragen Therapeut ... | HARVEY RICHARD A JR | Director | Option Exercise | A | 5.20 | 20,000 | 104,000 | 20,000 | |
| May 22 2007 | NABI | Aviragen Therapeut ... | FAHIM RAAFAT E F | Sr. VP Tech. & Prod ... | Option Exercise | A | 5.20 | 90,000 | 468,000 | 90,000 | |
| May 22 2007 | NABI | Aviragen Therapeut ... | FAHIM RAAFAT E F | Sr. VP Tech. & Prod ... | Grant | A | 0.00 | 30,000 | 0 | 126,730 | 96.7 K to 126.7 K (+31.01 %) |
| May 22 2007 | NABI | Aviragen Therapeut ... | CASTALDI DAVID L | Director | Option Exercise | A | 5.20 | 20,000 | 104,000 | 20,000 | |
| May 22 2007 | NABI | Aviragen Therapeut ... | DAVIS PETER B | Director | Option Exercise | A | 5.20 | 20,000 | 104,000 | 20,000 | |
| May 22 2007 | NABI | Aviragen Therapeut ... | DAVIS PETER B | Director | Grant | A | 0.00 | 3,846 | 0 | 7,814 | 4 K to 7.8 K (+96.93 %) |
| May 22 2007 | NABI | Aviragen Therapeut ... | Aryeh Jason | Director | Option Exercise | A | 5.20 | 20,000 | 104,000 | 20,000 | |
| May 11 2007 | NABI | Aviragen Therapeut ... | Third Point LLC | Buy | P | 5.25 | 200,000 | 1,050,000 | 6,890,000 | 6.7 M to 6.9 M (+2.99 %) | |
| May 11 2007 | NABI | Aviragen Therapeut ... | Third Point LLC | Buy | P | 5.25 | 135,000 | 708,750 | 6,690,000 | 6.6 M to 6.7 M (+2.06 %) | |
| May 11 2007 | NABI | Aviragen Therapeut ... | Third Point LLC | Buy | P | 5.25 | 225,000 | 1,181,250 | 6,555,000 | 6.3 M to 6.6 M (+3.55 %) | |
| May 11 2007 | NABI | Aviragen Therapeut ... | Third Point LLC | Buy | P | 5.13 | 230,000 | 1,179,900 | 6,330,000 | 6.1 M to 6.3 M (+3.77 %) | |
| May 11 2007 | NABI | Aviragen Therapeut ... | Third Point LLC | Buy | P | 5.15 | 350,000 | 1,802,500 | 6,100,000 | 5.8 M to 6.1 M (+6.09 %) | |
| Feb 20 2007 | NABI | Aviragen Therapeut ... | Hudson Leslie | Interim President & ... | Grant | A | 0.00 | 8,711 | 0 | 13,066 | 4.4 K to 13.1 K (+200.02 %) |
| Feb 20 2007 | NABI | Aviragen Therapeut ... | Hudson Leslie | Interim President & ... | Grant | A | 0.00 | 4,355 | 0 | 4,355 | 0 to 4.4 K |
| Nov 14 2006 | NABI | Aviragen Therapeut ... | LYNCH TIMOTHY P | Director | Option Exercise | A | 6.60 | 18,000 | 118,800 | 18,000 | |
| Nov 14 2006 | NABI | Aviragen Therapeut ... | Aryeh Jason | Director | Option Exercise | A | 6.60 | 18,000 | 118,800 | 18,000 | |
| Nov 07 2006 | NABI | Aviragen Therapeut ... | Third Point LLC | Sell | S | 6.22 | 27,342 | 170,067 | 5,750,000 | 5.8 M to 5.8 M (-0.47 %) | |
| Nov 07 2006 | NABI | Aviragen Therapeut ... | Third Point LLC | Buy | P | 6.25 | 27,342 | 170,888 | 5,777,342 | 5.8 M to 5.8 M (+0.48 %) | |
| Aug 17 2006 | NABI | Aviragen Therapeut ... | RASMUSSEN HENRIK S MD | Sr. VP Clin. Med. & ... | Buy | J | 2.73 | 3,573 | 9,749 | 84,262 | 80.7 K to 84.3 K (+4.43 %) |
| Aug 17 2006 | NABI | Aviragen Therapeut ... | MCLAIN THOMAS H | Chairman, CEO & Pre ... | Buy | J | 2.73 | 4,765 | 13,001 | 127,022 | 122.3 K to 127 K (+3.90 %) |
| Aug 17 2006 | NABI | Aviragen Therapeut ... | FAHIM RAAFAT E F | Sr. VP Tech. & Prod ... | Buy | J | 2.73 | 4,765 | 13,001 | 95,077 | 90.3 K to 95.1 K (+5.28 %) |
| Jun 13 2006 | NABI | Aviragen Therapeut ... | Siegel Jordan I | Sr. VP, Fin, CFO, C ... | Option Exercise | A | 5.10 | 40,000 | 204,000 | 40,000 | |
| Jun 13 2006 | NABI | Aviragen Therapeut ... | Siegel Jordan I | Sr. VP, Fin, CFO, C ... | Grant | A | 0.00 | 60,000 | 0 | 60,000 | 0 to 60 K |
| May 19 2006 | NABI | Aviragen Therapeut ... | HARVEY RICHARD A JR | Director | Option Exercise | M | 6.19 | 7,500 | 46,425 | 0 | |
| May 19 2006 | NABI | Aviragen Therapeut ... | HARVEY RICHARD A JR | Director | Grant | A | 6.19 | 7,500 | 46,425 | 30,996 | 23.5 K to 31 K (+31.92 %) |
| May 16 2006 | NABI | Aviragen Therapeut ... | SUDOVAR STEPHEN | Director | Option Exercise | A | 6.30 | 12,000 | 75,600 | 12,000 | |
| May 16 2006 | NABI | Aviragen Therapeut ... | SUDOVAR STEPHEN | Director | Grant | A | 6.30 | 4,365 | 27,500 | 8,362 | 4 K to 8.4 K (+109.21 %) |
| May 19 2006 | NABI | Aviragen Therapeut ... | COX GEOFFREY F | Director | Option Exercise | M | 6.19 | 5,250 | 32,498 | 2,250 | |
| May 19 2006 | NABI | Aviragen Therapeut ... | COX GEOFFREY F | Director | Grant | A | 6.19 | 5,250 | 32,498 | 23,771 | 18.5 K to 23.8 K (+28.35 %) |
| May 16 2006 | NABI | Aviragen Therapeut ... | RASMUSSEN HENRIK S MD | Sr. VP Clin. Med. & ... | Grant | A | 0.00 | 40,000 | 0 | 80,689 | 40.7 K to 80.7 K (+98.31 %) |
| May 16 2006 | NABI | Aviragen Therapeut ... | MCLAIN THOMAS H | Chairman, CEO & Pre ... | Option Exercise | A | 6.30 | 75,000 | 472,500 | 75,000 | |
| May 16 2006 | NABI | Aviragen Therapeut ... | MCLAIN THOMAS H | Chairman, CEO & Pre ... | Grant | A | 0.00 | 20,000 | 0 | 122,257 | 102.3 K to 122.3 K (+19.56 %) |
| May 16 2006 | NABI | Aviragen Therapeut ... | Logal Adam | Interim CFO, CAO an ... | Option Exercise | A | 6.30 | 20,000 | 126,000 | 20,000 | |
| May 16 2006 | NABI | Aviragen Therapeut ... | Johnson Joseph | Sr. VP, HR, IT, Bus ... | Option Exercise | A | 6.30 | 100,000 | 630,000 | 100,000 | |
| May 16 2006 | NABI | Aviragen Therapeut ... | JENCKES LINDA | Director | Option Exercise | A | 6.30 | 12,000 | 75,600 | 12,000 | |
| May 16 2006 | NABI | Aviragen Therapeut ... | COX GEOFFREY F | Director | Option Exercise | A | 6.30 | 12,000 | 75,600 | 12,000 | |
| May 16 2006 | NABI | Aviragen Therapeut ... | Hudson Leslie | Director | Option Exercise | A | 6.30 | 12,000 | 75,600 | 12,000 | |
| May 16 2006 | NABI | Aviragen Therapeut ... | HARVEY RICHARD A JR | Director | Option Exercise | A | 6.30 | 12,000 | 75,600 | 12,000 | |
| May 16 2006 | NABI | Aviragen Therapeut ... | FAHIM RAAFAT E F | Sr. VP Tech. & Prod ... | Grant | A | 0.00 | 40,000 | 0 | 90,312 | 50.3 K to 90.3 K (+79.50 %) |
| May 16 2006 | NABI | Aviragen Therapeut ... | CASTALDI DAVID L | Director | Option Exercise | A | 6.30 | 12,000 | 75,600 | 12,000 | |
| May 16 2006 | NABI | Aviragen Therapeut ... | CASTALDI DAVID L | Director | Grant | A | 6.30 | 3,174 | 19,996 | 49,189 | 46 K to 49.2 K (+6.90 %) |
| May 16 2006 | NABI | Aviragen Therapeut ... | DAVIS PETER B | Director | Option Exercise | A | 6.30 | 18,000 | 113,400 | 18,000 | |
| May 16 2006 | NABI | Aviragen Therapeut ... | DAVIS PETER B | Director | Grant | A | 6.30 | 3,968 | 24,998 | 3,968 | 0 to 4 K |
| Feb 28 2006 | NABI | Aviragen Therapeut ... | RASMUSSEN HENRIK S MD | Sr. VP Clin. Med. & ... | Option Exercise | A | 3.83 | 54,345 | 208,141 | 54,345 | |
| Feb 28 2006 | NABI | Aviragen Therapeut ... | RASMUSSEN HENRIK S MD | Sr. VP Clin. Med. & ... | Grant | A | 0.00 | 37,859 | 0 | 40,689 | 2.8 K to 40.7 K (+1,337.77 %) |
| Feb 28 2006 | NABI | Aviragen Therapeut ... | Johnson Joseph | Sr. VP, HR, IT, Bus ... | Option Exercise | A | 3.83 | 46,849 | 179,432 | 46,849 | |
| Feb 28 2006 | NABI | Aviragen Therapeut ... | Johnson Joseph | Sr. VP, HR, IT, Bus ... | Grant | A | 0.00 | 32,637 | 0 | 32,637 | 0 to 32.6 K |
| Feb 28 2006 | NABI | Aviragen Therapeut ... | MCLAIN THOMAS H | Chairman, CEO & Pre ... | Option Exercise | A | 3.83 | 84,329 | 322,980 | 84,329 | |
| Feb 28 2006 | NABI | Aviragen Therapeut ... | MCLAIN THOMAS H | Chairman, CEO & Pre ... | Grant | A | 0.00 | 58,746 | 0 | 102,257 | 43.5 K to 102.3 K (+135.01 %) |
| Feb 28 2006 | NABI | Aviragen Therapeut ... | FAHIM RAAFAT E F | Sr. VP Tech. & Prod ... | Option Exercise | A | 3.83 | 54,345 | 208,141 | 54,345 | |
| Feb 28 2006 | NABI | Aviragen Therapeut ... | FAHIM RAAFAT E F | Sr. VP Tech. & Prod ... | Grant | A | 0.00 | 37,859 | 0 | 50,312 | 12.5 K to 50.3 K (+304.02 %) |
| Nov 21 2005 | NABI | Aviragen Therapeut ... | MCLAIN THOMAS H | Chairman, CEO & Pre ... | Buy | I | 3.48 | 63,272 | 219,870 | 63,272 | 0 to 63.3 K |
| Nov 10 2005 | NABI | Aviragen Therapeut ... | SMITH MARK L | Sr. VP Fin., CFO, C ... | Buy | I | 3.52 | 17,393 | 61,136 | 17,393 | 0 to 17.4 K |
| Nov 08 2005 | NABI | Aviragen Therapeut ... | Jooste H Le Roux | Sr. VP, Glbl. Sales ... | Buy | P | 3.55 | 10,000 | 35,500 | 10,000 | 0 to 10 K |
| Nov 07 2005 | NABI | Aviragen Therapeut ... | FAHIM RAAFAT E F | Sr. VP Tech. & Prod ... | Buy | P | 3.46 | 5,000 | 17,300 | 11,859 | 6.9 K to 11.9 K (+72.90 %) |
| Sep 15 2005 | NABI | Aviragen Therapeut ... | SMITH MARK L | Sr. VP Fin., CFO, C ... | Buy | J | 10.58 | 1,228 | 12,995 | 19,908 | 18.7 K to 19.9 K (+6.57 %) |
| Sep 15 2005 | NABI | Aviragen Therapeut ... | MCLAIN THOMAS H | Chairman, CEO & Pre ... | Buy | J | 10.58 | 1,228 | 12,995 | 48,776 | 47.5 K to 48.8 K (+2.58 %) |
| Sep 15 2005 | NABI | Aviragen Therapeut ... | RASMUSSEN HENRIK S MD | Sr. VP Clin. Med. & ... | Buy | J | 10.58 | 921 | 9,746 | 1,876 | 955 to 1.9 K (+96.44 %) |
| Sep 15 2005 | NABI | Aviragen Therapeut ... | FAHIM RAAFAT E F | Sr. VP Tech. & Prod ... | Buy | J | 10.58 | 1,228 | 12,995 | 6,859 | 5.6 K to 6.9 K (+21.81 %) |
| Aug 22 2005 | NABI | Aviragen Therapeut ... | Hudson Leslie | Director | Option Exercise | A | 14.14 | 18,000 | 254,520 | 18,000 | |
| Jun 10 2005 | NABI | Aviragen Therapeut ... | FAHIM RAAFAT E F | Sr. VP Tech. & Prod ... | Buy | P | 12.15 | 2,000 | 24,300 | 5,631 | 3.6 K to 5.6 K (+55.08 %) |
| Jun 01 2005 | NABI | Aviragen Therapeut ... | COX GEOFFREY F | Director | Option Exercise | M | 3.25 | 7,500 | 24,375 | 0 | |
| Jun 01 2005 | NABI | Aviragen Therapeut ... | COX GEOFFREY F | Director | Payment of Exercise | F | 12.45 | 1,958 | 24,377 | 18,521 | 20.5 K to 18.5 K (-9.56 %) |
| Jun 01 2005 | NABI | Aviragen Therapeut ... | COX GEOFFREY F | Director | Buy | M | 3.25 | 7,500 | 24,375 | 20,479 | 13 K to 20.5 K (+57.79 %) |
| May 31 2005 | NABI | Aviragen Therapeut ... | HARVEY RICHARD A JR | Director | Option Exercise | M | 4.88 | 4,500 | 21,938 | 0 | |
| May 31 2005 | NABI | Aviragen Therapeut ... | HARVEY RICHARD A JR | Director | Buy | M | 4.88 | 4,500 | 21,938 | 23,496 | 19 K to 23.5 K (+23.69 %) |
| May 23 2005 | NABI | Aviragen Therapeut ... | FAHIM RAAFAT E F | Sr. VP Tech. & Prod ... | Buy | P | 12.17 | 1,000 | 12,170 | 3,631 | 2.6 K to 3.6 K (+38.01 %) |
| May 17 2005 | NABI | Aviragen Therapeut ... | SUDOVAR STEPHEN | Director | Option Exercise | A | 11.26 | 12,000 | 135,120 | 12,000 | |
| May 17 2005 | NABI | Aviragen Therapeut ... | JENCKES LINDA | Director | Option Exercise | A | 11.26 | 12,000 | 135,120 | 12,000 | |
| May 17 2005 | NABI | Aviragen Therapeut ... | JENCKES LINDA | Director | Option Exercise | M | 4.88 | 7,500 | 36,563 | 0 | |
| May 17 2005 | NABI | Aviragen Therapeut ... | JENCKES LINDA | Director | Buy | M | 4.88 | 7,500 | 36,563 | 21,747 | 14.2 K to 21.7 K (+52.64 %) |
| May 17 2005 | NABI | Aviragen Therapeut ... | HARVEY RICHARD A JR | Director | Option Exercise | A | 11.26 | 12,000 | 135,120 | 12,000 | |
| May 17 2005 | NABI | Aviragen Therapeut ... | EBRIGHT GEORGE W | Director | Option Exercise | A | 11.26 | 12,000 | 135,120 | 12,000 | |
| May 17 2005 | NABI | Aviragen Therapeut ... | CASTALDI DAVID L | Director | Option Exercise | A | 11.26 | 12,000 | 135,120 | 12,000 | |
| May 17 2005 | NABI | Aviragen Therapeut ... | COX GEOFFREY F | Director | Option Exercise | A | 11.26 | 12,000 | 135,120 | 12,000 | |
| May 17 2005 | NABI | Aviragen Therapeut ... | COX GEOFFREY F | Director | Grant | A | 11.26 | 1,776 | 19,998 | 12,979 | 11.2 K to 13 K (+15.85 %) |
| Apr 28 2005 | NABI | Aviragen Therapeut ... | EBRIGHT GEORGE W | Director | Option Exercise | M | 4.88 | 7,500 | 36,563 | 0 | |
| Apr 28 2005 | NABI | Aviragen Therapeut ... | EBRIGHT GEORGE W | Director | Sell | S | 11.15 | 7,500 | 83,647 | 12,325 | 19.8 K to 12.3 K (-37.83 %) |
| Apr 28 2005 | NABI | Aviragen Therapeut ... | EBRIGHT GEORGE W | Director | Buy | M | 4.88 | 7,500 | 36,563 | 19,825 | 12.3 K to 19.8 K (+60.85 %) |
| Apr 18 2005 | NABI | Aviragen Therapeut ... | CASTALDI DAVID L | Director | Option Exercise | M | 6.19 | 7,500 | 46,425 | 7,500 | |
| Apr 18 2005 | NABI | Aviragen Therapeut ... | CASTALDI DAVID L | Director | Buy | M | 6.19 | 7,500 | 46,425 | 46,015 | 38.5 K to 46 K (+19.47 %) |
| Mar 16 2005 | NABI | Aviragen Therapeut ... | SMITH MARK L | Sr. VP Fin., CFO, C ... | Option Exercise | A | 12.06 | 75,000 | 904,500 | 75,000 | |
| Mar 16 2005 | NABI | Aviragen Therapeut ... | MCLAIN THOMAS H | Chairman, CEO & Pre ... | Option Exercise | A | 12.06 | 150,000 | 1,809,000 | 150,000 | |
| Dec 20 2004 | NABI | Aviragen Therapeut ... | MCLAIN THOMAS H | Chairman, CEO & Pre ... | Buy | J | 12.30 | 1,057 | 13,001 | 47,548 | 46.5 K to 47.5 K (+2.27 %) |
| Dec 22 2004 | NABI | Aviragen Therapeut ... | Jooste H Le Roux | Sr. VP, Glbl. Sales ... | Option Exercise | A | 15.03 | 160,000 | 2,404,800 | 200,000 | |
| Dec 22 2004 | NABI | Aviragen Therapeut ... | Jooste H Le Roux | Sr. VP, Glbl. Sales ... | Option Exercise | A | 15.03 | 40,000 | 601,200 | 40,000 | |
| Dec 20 2004 | NABI | Aviragen Therapeut ... | SMITH MARK L | Sr. VP Fin., CFO, C ... | Buy | J | 12.30 | 1,057 | 13,001 | 18,680 | 17.6 K to 18.7 K (+6.00 %) |
| Dec 20 2004 | NABI | Aviragen Therapeut ... | SISKOWSKI GARY A | Sr. VP Sales & Mark ... | Buy | J | 12.30 | 79 | 972 | 2,890 | 2.8 K to 2.9 K (+2.81 %) |
| Dec 20 2004 | NABI | Aviragen Therapeut ... | Clark Richard | Sr. VP Admin. & Ch. ... | Buy | J | 12.30 | 53 | 652 | 53 | 0 to 53 |
| Dec 20 2004 | NABI | Aviragen Therapeut ... | RASMUSSEN HENRIK S MD | Sr. VP Clin. Med. & ... | Buy | J | 12.30 | 549 | 6,753 | 955 | 406 to 955 (+135.22 %) |
| Dec 20 2004 | NABI | Aviragen Therapeut ... | FAHIM RAAFAT E F | Sr. VP Tech. & Prod ... | Buy | J | 12.30 | 569 | 6,999 | 2,631 | 2.1 K to 2.6 K (+27.59 %) |
| Nov 15 2004 | NABI | Aviragen Therapeut ... | RASMUSSEN HENRIK S MD | Sr. VP. Clin. Med. ... | Option Exercise | A | 15.56 | 160,000 | 2,489,600 | 160,000 | |
| Nov 15 2004 | NABI | Aviragen Therapeut ... | FAHIM RAAFAT E F | Sr. VP., Tech. & Pr ... | Option Exercise | A | 15.56 | 160,000 | 2,489,600 | 160,000 | |
| Aug 10 2004 | NABI | Aviragen Therapeut ... | MCLAIN THOMAS H | Chairman, CEO and P ... | Buy | P | 10.45 | 110 | 1,150 | 240 | 130 to 240 (+84.62 %) |
| Jun 22 2004 | NABI | Aviragen Therapeut ... | SMITH MARK L | Sr.VP. Fin., CFO, C ... | Buy | J | 9.23 | 1,337 | 12,342 | 17,623 | 16.3 K to 17.6 K (+8.21 %) |
| Jun 22 2004 | NABI | Aviragen Therapeut ... | SISKOWSKI GARY A | Sr. VP Sales & Mark ... | Buy | J | 9.23 | 106 | 978 | 2,811 | 2.7 K to 2.8 K (+3.92 %) |
| Jun 22 2004 | NABI | Aviragen Therapeut ... | RASMUSSEN HENRIK S MD | Sr. VP. Clin. Med. ... | Buy | J | 9.23 | 406 | 3,748 | 406 | 0 to 406 |
| Jun 22 2004 | NABI | Aviragen Therapeut ... | MCLAIN THOMAS H | President and CEO | Buy | J | 9.23 | 1,408 | 12,997 | 46,491 | 45.1 K to 46.5 K (+3.12 %) |
| Jun 22 2004 | NABI | Aviragen Therapeut ... | GURY DAVID J | Director | Gift | G | 0.00 | 5,000 | 0 | 495,313 | 500.3 K to 495.3 K (-1.00 %) |
| Jun 22 2004 | NABI | Aviragen Therapeut ... | FAHIM RAAFAT E F | Sr. VP., Tech. & Pr ... | Buy | J | 9.23 | 515 | 4,754 | 2,062 | 1.5 K to 2.1 K (+33.29 %) |
| Jun 15 2004 | NABI | Aviragen Therapeut ... | CASTALDI DAVID L | Director | Option Exercise | M | 4.88 | 7,500 | 36,563 | 0 | |
| Jun 15 2004 | NABI | Aviragen Therapeut ... | CASTALDI DAVID L | Director | Buy | M | 4.88 | 7,500 | 36,563 | 38,515 | 31 K to 38.5 K (+24.18 %) |
| May 18 2004 | NABI | Aviragen Therapeut ... | SUDOVAR STEPHEN | Director | Option Exercise | A | 16.65 | 10,000 | 166,500 | 10,000 | |
| May 18 2004 | NABI | Aviragen Therapeut ... | SMITH MARK L | Sr.VP. Fin., CFO, C ... | Option Exercise | A | 16.65 | 10,472 | 174,359 | 10,472 | |
| May 18 2004 | NABI | Aviragen Therapeut ... | SISKOWSKI GARY A | Sr. VP Sales & Mark ... | Option Exercise | A | 16.65 | 5,448 | 90,709 | 5,448 | |
| May 18 2004 | NABI | Aviragen Therapeut ... | RASMUSSEN HENRIK S MD | Sr. VP. Clin. Med. ... | Option Exercise | A | 16.65 | 8,532 | 142,058 | 8,532 | |
| May 18 2004 | NABI | Aviragen Therapeut ... | MCLAIN THOMAS H | Chairman, President ... | Option Exercise | A | 16.65 | 15,514 | 258,308 | 15,514 | |
| May 18 2004 | NABI | Aviragen Therapeut ... | JENCKES LINDA | Director | Option Exercise | A | 16.65 | 10,000 | 166,500 | 10,000 | |
| May 18 2004 | NABI | Aviragen Therapeut ... | HARVEY RICHARD A JR | Director | Option Exercise | A | 16.65 | 10,000 | 166,500 | 10,000 | |
| May 18 2004 | NABI | Aviragen Therapeut ... | CASTALDI DAVID L | Director | Option Exercise | A | 16.65 | 10,000 | 166,500 | 10,000 | |
| May 18 2004 | NABI | Aviragen Therapeut ... | FAHIM RAAFAT E F | Sr. VP., Tech. & Pr ... | Option Exercise | A | 16.65 | 8,143 | 135,581 | 8,143 | |
| May 18 2004 | NABI | Aviragen Therapeut ... | COX GEOFFREY F | Director | Option Exercise | A | 16.65 | 10,000 | 166,500 | 10,000 | |
| May 18 2004 | NABI | Aviragen Therapeut ... | COX GEOFFREY F | Director | Grant | A | 16.65 | 1,201 | 19,997 | 11,203 | 10 K to 11.2 K (+12.01 %) |
| May 18 2004 | NABI | Aviragen Therapeut ... | EBRIGHT GEORGE W | Director | Option Exercise | A | 16.65 | 10,000 | 166,500 | 10,000 | |
| May 05 2004 | NABI | Aviragen Therapeut ... | EBRIGHT GEORGE W | Director | Option Exercise | M | 2.81 | 7,500 | 21,098 | 0 | |
| May 05 2004 | NABI | Aviragen Therapeut ... | EBRIGHT GEORGE W | Director | Sell | S | 17.10 | 1,253 | 21,426 | 12,325 | 13.6 K to 12.3 K (-9.23 %) |
| May 05 2004 | NABI | Aviragen Therapeut ... | EBRIGHT GEORGE W | Director | Buy | M | 2.81 | 7,500 | 21,098 | 13,578 | 6.1 K to 13.6 K (+123.40 %) |
| May 17 2004 | NABI | Aviragen Therapeut ... | JENCKES LINDA | Director | Option Exercise | M | 2.81 | 7,500 | 21,098 | 0 | |
| May 17 2004 | NABI | Aviragen Therapeut ... | JENCKES LINDA | Director | Buy | M | 2.81 | 7,500 | 21,098 | 14,247 | 6.7 K to 14.2 K (+111.16 %) |
| Apr 06 2004 | NABI | Aviragen Therapeut ... | GURY DAVID J | Director | Option Exercise | M | 7.06 | 6,250 | 44,144 | 188,817 | |
| Apr 06 2004 | NABI | Aviragen Therapeut ... | GURY DAVID J | Director | Payment of Exercise | F | 16.09 | 3,496 | 56,251 | 500,314 | 503.8 K to 500.3 K (-0.69 %) |
| Apr 06 2004 | NABI | Aviragen Therapeut ... | GURY DAVID J | Director | Buy | M | 7.06 | 6,250 | 44,144 | 503,810 | 497.6 K to 503.8 K (+1.26 %) |
| Apr 28 2004 | NABI | Aviragen Therapeut ... | HARVEY RICHARD A JR | Director | Option Exercise | M | 4.88 | 3,000 | 14,625 | 4,500 | |
| Apr 28 2004 | NABI | Aviragen Therapeut ... | HARVEY RICHARD A JR | Director | Option Exercise | M | 2.81 | 7,500 | 21,098 | 0 | |
| Apr 28 2004 | NABI | Aviragen Therapeut ... | HARVEY RICHARD A JR | Director | Buy | M | 4.88 | 3,000 | 14,625 | 18,996 | 16 K to 19 K (+18.75 %) |
| Apr 28 2004 | NABI | Aviragen Therapeut ... | HARVEY RICHARD A JR | Director | Buy | M | 2.81 | 7,500 | 21,098 | 15,996 | 8.5 K to 16 K (+88.28 %) |
| Mar 26 2004 | NABI | Aviragen Therapeut ... | FAHIM RAAFAT E F | Sr. VP., Tech. & Pr ... | Option Exercise | A | 14.92 | 43,116 | 643,291 | 43,116 |